Bringing a therapy to market can cost billions. Now with support from the FDA and EMA, the industry is ready to realize the promise of risk-based monitoring. We have been using elements of RBM since 2001 as a smarter, more efficient approach to clinical trial execution that focuses on critical data. In these multimedia presentations, we will share recent research insights and real experiences using a modernized approach to risk-based monitoring.